The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
Launched by PEKING UNIVERSITY · Apr 10, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is examining how the immune system and nutritional status of patients with advanced gastric cancer change when they receive preoperative treatments, such as chemotherapy or chemoradiotherapy. Researchers want to understand if these changes can help predict a patient’s recovery and overall health after treatment. By studying these factors, they hope to improve patient care and treatment outcomes for those battling gastric cancer.
To be eligible for this trial, participants must have a confirmed diagnosis of advanced gastric cancer and have received preoperative chemotherapy or chemoradiotherapy. This trial is open to all adults, regardless of age or gender. If you decide to participate, you will undergo assessments to measure your immune and nutritional status, which will help the researchers gather important information on how these factors relate to your treatment journey. It’s an opportunity to contribute to valuable research that may benefit future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically confirmed adenocarcinoma
- • Received neoadjuvant (preoperative) chemotherapy or chemoradiotherapy
- • Diagnosed clinical advanced gastric cancer or esophagogastric cancer
- Exclusion Criteria:
- • Lack of immuno-nutrition data
About Peking University
Peking University is a prestigious institution located in Beijing, China, recognized for its commitment to advancing medical research and education. As a clinical trial sponsor, Peking University leverages its extensive academic resources and collaborative networks to drive innovative healthcare solutions. The university's focus on rigorous scientific methodologies and adherence to ethical standards ensures the integrity and reliability of its clinical research initiatives. By fostering interdisciplinary partnerships, Peking University aims to translate groundbreaking discoveries into tangible health benefits, contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Jiafu Ji, M.D., Ph.D.
Principal Investigator
Peking University Cancer Hospital & Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials